Gomekli™ (mirdametinib) has emerged as a significant advancement in the treatment of neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN), offering new hope to patients aged 2 years and older. 🧬 Understanding Neurofibromatosis Type…
The Alyftrek drug, a groundbreaking once-daily triple-combination therapy, received U.S. Food and Drug Administration (FDA) approval in December 2024 for the treatment of cystic fibrosis (CF) in patients aged six and older. This approval represents a…
Based on the TROPION-Breast01 trial, Daiichi Sankyo and AstraZeneca’s DATROWAY was approved for the first time in the European Union. The trial showed a 37% reduction in the risk of disease progression or death compared…
Epilepsy is a chronic neurological disorder that affects an estimated 65 million people worldwide. Briviact (brivaracetam) is a medication commonly used to treat seizures; understanding how it works and what to expect is crucial for…
Akynzeo capsule is an FDA-approved antiemetic medication specifically designed to address both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV). As chemotherapy remains a cornerstone of cancer treatment, its debilitating side effects –…
NEW YORK, April 8, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.(TGTX) announced today that it will publish data on BRIUMVI® (ublituximab-xiiy) for the treatment of patients with relapsing multiple sclerosis (RMS). Michael S. Weiss, Chief…
In September 2024, the U.S. Food and Drug Administration (FDA) approved Cobenfy (xanomeline and trospium chloride), marking the first new class of schizophrenia treatment in over three decades. Developed by Karuna Therapeutics and acquired by…
Major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide in 2008 by WHO, which has projected that this disease will rank first by 2030. If you are…
In a landmark advancement for nuclear cardiology, GE HealthCare has launched Flyrcado™ (flurpiridaz F 18), the first FDA-approved unit-dose positron emission tomography (PET) myocardial perfusion imaging (MPI) agent for detecting coronary artery disease (CAD). Approved in September 2024 and commercially available in select…
The U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib), developed by Genentech, a member of the Roche Group, in combination with palbociclib and fulvestrant, for the treatment of adults with endocrine-resistant. PIK3CA-mutated, hormone…
In October 2024, the U.S. Food and Drug Administration (FDA) approved Orlynvah™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited or no alternative oral antibacterial…
In November 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Ziihera® (zanidatamab-hrii), marking a significant advancement in the treatment of previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer…
